Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
Conditions: Nipah Virus Infection Interventions: Biological: PHV02; Biological: Lactated Ringer ' s Sponsors: Public Health Vaccines LLC; Coalition for Epidemic Preparedness Innovations Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials
NIH Launches Clinical Trial of mRNA Nipah Virus Vaccine
July 11, 2022 -- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an investigational vaccine to prevent infection with Nipah virus.... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 11, 2022 Category: Pharmaceuticals Source Type: clinical trials
VRC 322/DMID 21-0016: A Phase I, Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
Condition: Nipah Virus Infection Intervention: Biological: mRNA -1215 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 1, 2022 Category: Research Source Type: clinical trials
Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
Condition: Nipah Virus Infection Intervention: Biological: mRNA -1215 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 1, 2022 Category: Research Source Type: clinical trials
VRC 322/DMID 21-0016: A Phase I, Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
Condition: Nipah Virus Infection Intervention: Biological: mRNA -1215 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 1, 2022 Category: Research Source Type: clinical trials
Safety and Immunogenicity of a Nipah Virus Vaccine
Condition: Nipah Virus Infection Interventions: Biological: HeV-sG-V; Biological: Normal Saline Placebo Sponsors: Profectus BioSciences, Inc.; PATH; Coalition for Epidemic Preparedness Initiative (CEPI); Cincinnati Children's Hospital Medical Center (CCHMC) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2019 Category: Research Source Type: clinical trials
